查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1523035

钙拮抗剂市场报告：2030 年趋势、预测与竞争分析

Calcium Channel Blockers Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

钙拮抗剂的趋势与预测

预计2024年至2030年全球钙拮抗剂市场将以5.4%的复合年增长率成长。该市场的主要驱动力是老年人口的显着增长、多模式治疗方法的普及以及心血管疾病盛行率的增加。全球钙通道阻断剂市场前景广阔，高血压、心绞痛、心律不整和肥厚性心肌病市场有机会。

钙拮抗剂按细分市场

包含按药物类别、给药途径、分销管道、应用和地区分類的钙通道阻断剂的全球市场预测。

钙拮抗剂市场洞察

Lucintel 预测，由于二氢吡啶在高血压治疗中的应用不断增加，因此在预测期内，二氢吡啶仍将是最大的市场区隔。

高血压仍然是该市场中最大的部分。

由于心血管疾病的高发生率和人口老化，北美在预测期内将继续成为最大的市场。

常问问题

Q1.市场成长预测是多少：

A1. 2024年至2030年，全球钙通道阻断剂市场预计将以5.4%的复合年增长率成长。

Q2. 影响市场成长的关键驱动因素是：

A2. 此市场的主要驱动力是老年人口的显着增长、多模式治疗方法的增加以及心血管疾病盛行率的增加。

Q3.市场的主要细分市场是：

A3. 钙通道阻断剂市场前景广阔，高血压、心绞痛、心律不整和肥厚性心肌病市场充满机会。

Q4.市场的主要企业是：

A4. 生产钙拮抗剂的主要企业如下：

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo

Q5.未来最大的细分市场是什么？

A5.Lucintel 预测，由于二氢吡啶类药物在高血压治疗中的应用不断增加，因此在预测期内，二氢吡啶类药物将继续成为最大的市场区隔。

Q6.未来五年预计哪些地区的市场成长最大？

A6. 由于心血管疾病的高发生率和人口老化，北美在预测期内仍将是最大的市场。

Q7. 可以客製化报告吗？

A7。

目录

第一章执行摘要

第二章全球钙拮抗剂市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球钙拮抗剂市场趋势（2018-2023）与预测（2024-2030）
  • 全球钙拮抗剂市场：依药物类别
    • 苯烷基胺
    • 苯并氮平
    • 二氢吡啶
  • 全球钙通道阻断剂市场：依给药途径
    • 口服
    • 胃肠外的
  • 全球钙拮抗剂市场：按通路
    • 医院药房
    • 零售药房
    • 网路药房
  • 全球钙拮抗剂市场：依应用分类
    • 高血压
    • 心绞痛
    • 心律不整
    • 肥厚型心肌病
    • 其他的

第四章 2018-2030年区域市场趋势及预测分析

  • 按地区分類的全球钙通道阻断剂市场
  • 北美钙通道阻断剂市场
  • 欧洲钙通道阻断剂市场
  • 亚太地区钙拮抗剂市场
  • 其他区域钙拮抗剂市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按药物类别分類的全球钙拮抗剂市场成长机会
    • 按途径的全球钙拮抗剂市场成长机会
    • 全球钙拮抗剂市场成长机会（按分销管道）
    • 钙通道阻断剂的全球市场成长机会（按应用）
    • 全球钙拮抗剂市场成长机会（按地区）
  • 全球钙拮抗剂市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球钙拮抗剂市场产能扩张
    • 全球钙通道阻断剂市场的合併、收购与合资企业
    • 认证和许可

第七章主要企业概况

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo
简介目录

Calcium Channel Blockers Trends and Forecast

The future of the global calcium channel blockers market looks promising with opportunities in the hypertension, angina, arrhythmia, and hypertrophic cardiomyopathy markets. The global calcium channel blockers market is expected to grow with a CAGR of 5.4% from 2024 to 2030. The major drivers for this market are significant surge in the elderly demographic, increasing accessibility of combined therapeutic approaches, and growing prevalence rate of cardiovascular diseases.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Calcium Channel Blockers by Segment

The study includes a forecast for the global calcium channel blockers by drug class, route of administration, distribution channel, application, and region.

Calcium Channel Blockers Market by Drug Class [Shipment Analysis by Value from 2018 to 2030]:

  • Phenylalkylamine
  • Benzothizepine
  • Dihydropyridine

Calcium Channel Blockers Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Parenteral

Calcium Channel Blockers Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Calcium Channel Blockers Market by Application [Shipment Analysis by Value from 2018 to 2030]:

  • Hypertension
  • Angina
  • Arrhythmia
  • Hypertrophic Cardiomyopathy
  • Others

Calcium Channel Blockers Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Calcium Channel Blockers Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies calcium channel blockers companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the calcium channel blockers companies profiled in this report include-

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo

Calcium Channel Blockers Market Insights

Lucintel forecasts that dihydropyridine will remain the largest segment over the forecast period due to its increasing adoption for treating hypertension.

Within this market, hypertension will remain the largest segment.

North America will remain the largest segment over the forecast period due to high prevalence of cardiovascular diseases and rising aging population in the region.

Features of the Global Calcium Channel Blockers Market

Market Size Estimates: Calcium channel blockers market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Calcium channel blockers market size by various segments, such as by drug class, route of administration, distribution channel, application, and region in terms of value ($B).

Regional Analysis: Calcium channel blockers market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug classes, route of administration, distribution channels, application, and regions for the calcium channel blockers market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the calcium channel blockers market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for calcium channel blockers market?

Answer: The global calcium channel blockers market is expected to grow with a CAGR of 5.4% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the calcium channel blockers market?

Answer: The major drivers for this market are significant surge in the elderly demographic, increasing accessibility of combined therapeutic approaches and growing prevalence rate of cardiovascular diseases.

Q3. What are the major segments for calcium channel blockers market?

Answer: The future of the calcium channel blockers market looks promising with opportunities in the hypertension, angina, arrhythmia, and hypertrophic cardiomyopathy markets.

Q4. Who are the key calcium channel blockers market companies?

Answer: Some of the key calcium channel blockers companies are as follows:

  • Pfizer
  • Teva Pharmaceutical Industries
  • Bausch Health Company
  • Novartis
  • AstraZeneca
  • Merck
  • GSK
  • Bayer
  • Sun Pharmaceutical Industries
  • Daiichi Sankyo

Q5. Which calcium channel blockers market segment will be the largest in future?

Answer: Lucintel forecasts that dihydropyridine will remain the largest segment over the forecast period due to its increasing adoption for treating hypertension.

Q6. In calcium channel blockers market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest segment over the forecast period due to high prevalence of cardiovascular diseases and rising aging population in the region.

Q7. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the calcium channel blockers market by drug class (phenylalkylamine, benzothizepine, and dihydropyridine), route of administration (oral and parenteral), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), application (hypertension, angina, arrhythmia, hypertrophic cardiomyopathy, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Calcium Channel Blockers Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Calcium Channel Blockers Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Calcium Channel Blockers Market by Drug Class
    • 3.3.1: Phenylalkylamine
    • 3.3.2: Benzothizepine
    • 3.3.3: Dihydropyridine
  • 3.4: Global Calcium Channel Blockers Market by Route of Administration
    • 3.4.1: Oral
    • 3.4.2: Parenteral
  • 3.5: Global Calcium Channel Blockers Market by Distribution Channel
    • 3.5.1: Hospital Pharmacies
    • 3.5.2: Retail Pharmacies
    • 3.5.3: Online Pharmacies
  • 3.6: Global Calcium Channel Blockers Market by Application
    • 3.6.1: Hypertension
    • 3.6.2: Angina
    • 3.6.3: Arrhythmia
    • 3.6.4: Hypertrophic Cardiomyopathy
    • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Calcium Channel Blockers Market by Region
  • 4.2: North American Calcium Channel Blockers Market
    • 4.2.1: North American Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.2.2: North American Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.3: European Calcium Channel Blockers Market
    • 4.3.1: European Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.3.2: European Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.4: APAC Calcium Channel Blockers Market
    • 4.4.1: APAC Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.4.2: APAC Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others
  • 4.5: ROW Calcium Channel Blockers Market
    • 4.5.1: ROW Calcium Channel Blockers Market by Drug Class: Phenylalkylamine, Benzothizepine, and Dihydropyridine
    • 4.5.2: ROW Calcium Channel Blockers Market by Application: Hypertension, Angina, Arrhythmia, Hypertrophic Cardiomyopathy, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Calcium Channel Blockers Market by Drug Class
    • 6.1.2: Growth Opportunities for the Global Calcium Channel Blockers Market by Route of Administration
    • 6.1.3: Growth Opportunities for the Global Calcium Channel Blockers Market by Distribution Channel
    • 6.1.4: Growth Opportunities for the Global Calcium Channel Blockers Market by Application
    • 6.1.5: Growth Opportunities for the Global Calcium Channel Blockers Market by Region
  • 6.2: Emerging Trends in the Global Calcium Channel Blockers Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Calcium Channel Blockers Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Calcium Channel Blockers Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Pfizer
  • 7.2: Teva Pharmaceutical Industries
  • 7.3: Bausch Health Company
  • 7.4: Novartis
  • 7.5: AstraZeneca
  • 7.6: Merck
  • 7.7: GSK
  • 7.8: Bayer
  • 7.9: Sun Pharmaceutical Industries
  • 7.10: Daiichi Sankyo